Clarity

Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting

Retrieved on: 
Thursday, October 19, 2023
Week, Alzheimer's disease, Amyloid, Patient, AD, Biogen, Clarity, MAPT, HIV disease progression rates, Clinical trial, BIIB, PET, LTE, Caregiver, CLARITY, Biomarker, Safety, Pharmaceutical industry, Medical imaging

CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from its Alzheimer’s disease portfolio at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) meeting taking place October 24-27 in Boston, Mass.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from its Alzheimer’s disease portfolio at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) meeting taking place October 24-27 in Boston, Mass.
  • The presentations will advance the understanding of Alzheimer’s disease with data on different treatment approaches, predictive analysis of disease progression, and clinical meaningfulness of amyloid removal for patients and their caregivers.
  • The presentation will include the latest data from the CLARITY AD optional tau PET longitudinal sub-study.
  • Oral presentation: Precision medicine analysis of heterogeneity in individual-level treatment response to beta-amyloid removal in early Alzheimer’s disease: Thursday, October 26, 4:35 p.m.

Eisai to Present New Data from LEQEMBI (Lecanemab-Irmb) Phase 3 Clarity Ad Study and Other Alzheimer's Disease Pipeline Research at The Clinical Trials on Alzheimer's Disease (CTAD) Conference

Retrieved on: 
Monday, October 16, 2023
Senior, PAM, Donanemab, Lecanemab, Death, Amyloid, Brain, Clinical trial, PET, Disease, Clinical research, Neurology, Clarity, EDT, AD, Tropomyosin receptor kinase A, Research, Amyloid beta, Pharmaceutical industry, Medical imaging, MD, MPH, Alzheimer's disease, Eisai

The conference will be held in Boston, Massachusetts, United States and virtually from October 24 to 27, 2023.

Key Points: 
  • The conference will be held in Boston, Massachusetts, United States and virtually from October 24 to 27, 2023.
  • At the conference, Eisai will present data and research in five oral and ten poster presentations.
  • "We look forward to sharing the new LEQEMBI low-tau subgroup data and subcutaneous data at CTAD 2023."
  • The full list of presentations about Eisai assets and research, click the link: www.eisai.com/news/2023/news202365.html

Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of Clarity

Retrieved on: 
Wednesday, October 11, 2023
Entertainment, Biotechnology, Celebrity, Other Education, Health, Music, Pharmaceutical, General Health, Education, Diagnosis, Multimedia, Partnership, Human, Inflammation, Dermatology, Atopic dermatitis, Dermatitis, Disease, Moments of Clarity, AD, Skin, Patient, Nursing, Clarity

View the full release here: https://www.businesswire.com/news/home/20231011336627/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231011336627/en/
    As someone who also lives with eczema, Mandy Moore understands the challenges of the condition.
  • Through Moments of Clarity, Mandy encourages others with eczema to take charge of their health and talk to their dermatologists about finding an appropriate treatment.
  • After seeing a dermatologist, I was diagnosed with eczema," said Mandy Moore.
  • “We are grateful to Mandy Moore for partnering with us and lending her voice to help others know they are not alone in their journeys.”
    * Mandy Moore has been compensated for her participation.

Clarity AI Honored in Fast Company Magazine’s 2023 “Brands That Matter” List

Retrieved on: 
Wednesday, October 4, 2023
Environment, Technology, Finance, Professional Services, Small Business, Sustainability, Software, Environmental, Social and Governance (ESG), Data Management, Klarna, Clarity, Investment Week, Climate, Aspiration, Research, Marketing

Clarity AI , the leading sustainability technology platform, has been named to Fast Company’s prestigious annual list of “Brands That Matter” in 2023 .

Key Points: 
  • Clarity AI , the leading sustainability technology platform, has been named to Fast Company’s prestigious annual list of “Brands That Matter” in 2023 .
  • In response to the increasing need of consumers to gain insight into the environmental impact of their purchases, Clarity AI has partnered with Klarna, a leading global payments provider and shopping service, and Aspiration, a top global climate finance company, as a step forward in democratizing access to sustainability insights.
  • In addition to this award, earlier this year Clarity AI was named to the “2023 World’s Most Innovative Companies” list by Fast Company.
  • Most recently, they have been awarded the Best Sustainable Investment Research & Ratings Provider by Investment Week.

Clarity AI Introduces its First SFDR-aligned Sustainable Investment Index Methodology

Retrieved on: 
Tuesday, October 3, 2023
Professional Services, Data Management, Data Analytics, Environment, Technology, Sustainability, Finance, 2016 European Union bank stress test, Pais, ETF, Taxonomy, Sustainable Development Goals, Index, Organization, Clarity, Investment, SFDR, Strategic sustainable investing, Asset management, EU

Clarity AI's methodology is being used in indices that target companies at the forefront of key innovative industries -- such as electric vehicles and sustainable infrastructure -- and ETFs based on those indices. It can also be applied to broader market indices and funds where investors want to integrate sustainable objectives. It provides a transparent, clear, comprehensive, and robust framework for classifying organizations, funds, and indices as sustainable investments, ensuring greater confidence for investors who seek to align their portfolios with sustainable principles.

Key Points: 
  • Clarity AI, the leading sustainability technology platform, has launched a groundbreaking Sustainable Investment index and ETF methodology, which aligns with the Sustainable Finance Disclosure Regulation (SFDR).
  • The methodology marks a significant step forward for index and ETF providers to build, define and/or market products that fall within the European Union's definition of Sustainable Investment, outlined in Article 2(17) of the SFDR.
  • Importantly, as the regulation requires financial market participants to determine what is considered a sustainable investment, Clarity AI’s methodology is customizable.
  • Ani Widham, Senior Product Manager at Clarity AI commented, "The successful implementation of Clarity AI’s Sustainable Investment methodology into Indices and ETFs sets a precedent for sustainable investing that can shape the future of the financial markets.

MCRA Assists Ceribell with Obtaining FDA Breakthrough Device Designation, FDA Marketing Authorization, and CMS NTAP Reimbursement for ClarityPro Device

Retrieved on: 
Monday, September 25, 2023
CMS, NTAP, Marketing, Software, Food and Drug Administration, MCRA, Market access, Clarity, Clinical trial, Hospital, Digital health, Patient, Physician, Machine learning, ESE, EEG, Quality assurance, Neurology, Diagnosis, Digital, ICU, FDA, Breakthrough, Food, Medical device, Policy, Computer security

MCRA's Neurology and Digital Health regulatory teams played a key role in successfully achieving both the Breakthrough Device Designation and clearance of the 510(k) premarket notification for Ceribell's ClarityPro device.

Key Points: 
  • MCRA's Neurology and Digital Health regulatory teams played a key role in successfully achieving both the Breakthrough Device Designation and clearance of the 510(k) premarket notification for Ceribell's ClarityPro device.
  • In addition, MCRA's Reimbursement, Health Economics, and Market Access team provided Ceribell with valuable insights, analyses, and strategic guidance on the NTAP application.
  • Raymond Woo, CTO of Ceribell said, "Ceribell feels extremely fortunate to have partnered with MCRA on ClarityPro as well as other projects.
  • The FDA Breakthrough Device program is itself relatively new, and the CMS NTAP alternative pathway for breakthrough devices is an even more recent development.

"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan

Retrieved on: 
Monday, September 25, 2023
Amyloid-related imaging abnormalities, PMID, Outline, Clinical trial, Marketing, The New England Journal of Medicine, Deficit spending, Pathology, Ministry of Health, Labour and Welfare, Research, Brain, Siderosis, History, MCI, The Different Forms of Flowers on Plants of the Same Species, Clarity, Ministry, ARIA, Dementia, HIV disease progression rates, Patient, Immunoglobulin G, Superficial siderosis, PLOS One, Co-promotion, Ministry of Health (Kuwait), Therapy, Headache, Neurotoxicity, Disease, ADCS, Pharmaceutical industry, Alzheimer's disease, Biogen, Amyloid beta, Health, Eisai

Japan is the second country to grant approval, following the traditional approval in the U.S. in July 2023.

Key Points: 
  • Japan is the second country to grant approval, following the traditional approval in the U.S. in July 2023.
  • In the Clarity AD clinical trial, treatment with LEQEMBI reduced clinical decline on CDR-SB by 27% at 18 months compared to placebo.
  • "Today LEQEMBI received approval, making it the first approved anti-amyloid Alzheimer's disease treatment shown to reduce the rate of disease progression and to slow cognitive impairment in the early and mild dementia stages of the disease in Japan.
  • In Japan, Eisai and Biogen Japan will co-promote LEQEMBI, with Eisai distributing the product as the Marketing Authorization Holder.

1 in 5 Companies Have Disparities between CDP GHG Emissions Reporting and their Sustainability Reports

Retrieved on: 
Friday, September 15, 2023
Consulting, Data Management, Technology, Professional Services, Business, Other Technology, Green Technology, Artificial Intelligence, Other Professional Services, Environment, Sustainability, Carbon, CDP, Disclosure, Clarity, ESG, Greenhouse gas, Carbon Disclosure Project, GHG, Research, Natural Product Research, Innovation, Explosive, Renewable energy

New research from Clarity AI , the leading sustainability technology platform, reveals discrepancies in one in five companies between their reported CDP data and the emissions data reported in their own sustainability reports.

Key Points: 
  • New research from Clarity AI , the leading sustainability technology platform, reveals discrepancies in one in five companies between their reported CDP data and the emissions data reported in their own sustainability reports.
  • A study conducted by Clarity AI encompassing around 1,500 data points from more than 850 companies that disclosed climate data to the CDP in 2022, revealed that one in every five companies disclose different GHG emissions in the CDP questionnaire and in their Annual or Sustainability reports.
  • The data shows that the discrepancy rate drops from 27% for non-verified companies to 15% for verified companies.
  • These differences are explained by human errors in 80% of the cases when companies report to the CDP, or by the use of inconsistent reporting methodologies – for example when companies report only their headquarters’ emissions to the CDP and their full emissions in their own reports.

HighLife Launches a New Large Annulus Valve in Ongoing Clinical Studies for Patients Suffering From Mitral Regurgitation

Retrieved on: 
Wednesday, September 6, 2023
Research, Medical Devices, Clinical Trials, Health Technology, Cardiology, Other Health, Biotechnology, General Health, Health, Science, Structural heart disease, LAV, LAV 6, MR, Mitral valve, Trial of the century, SAS, Clarity, Mitral regurgitation, LVOT, Patient, Risk, Highlife, Medical imaging, Pharmaceutical industry

HighLife SAS, a medtech company focused on the development of a novel Trans-Septal Mitral Valve Replacement (“TSMVR”) system to treat patients suffering from moderate to severe mitral regurgitation (MR), announced today the introduction of a new valve size in its clinical trials, the Large Annulus Valve (LAV), designed for patients with larger anatomies.

Key Points: 
  • HighLife SAS, a medtech company focused on the development of a novel Trans-Septal Mitral Valve Replacement (“TSMVR”) system to treat patients suffering from moderate to severe mitral regurgitation (MR), announced today the introduction of a new valve size in its clinical trials, the Large Annulus Valve (LAV), designed for patients with larger anatomies.
  • Among patients with moderate to severe MR, there has been a lack of treatment options for patients with large annuli.
  • “HighLife’s solution and this new valve size are a game-changer for our patients with Mitral Regurgitation.
  • We look forward to enroll and treat more patients in HighLife’s clinical study !”
    “We are excited to launch the Large Annulus Valve.

Clarity AI Integrates Sustainability Data into SimCorp to Drive Impact Investing and Regulatory Alignment

Retrieved on: 
Tuesday, August 29, 2023
Professional Services, Data Management, Environmental, Social and Governance (ESG), Environment, Technology, Sustainability, Finance, United Nations Sustainable Development Group, Partnership, SDG, Head, Taxonomy, Article, Data collection, Sustainable Development Goals, EU taxonomy for sustainable activities, Silver, SimCorp, Clarity, Data science, Data, Investment, Risk, SFDR, BNP Paribas Asset Management, ESG, Automation, Cryptocurrency, Renewable energy, Medical device, EU

Global sustainability technology company, Clarity AI, announces the integration of its data offering into SimCorp’s investment management platform.

Key Points: 
  • Global sustainability technology company, Clarity AI, announces the integration of its data offering into SimCorp’s investment management platform.
  • “Amid the rapid evolution and diversification of regulatory frameworks and increasing demand for access to high quality, accurate, timely sustainability data, Clarity AI stands out by delivering a flexible, and scalable solution.
  • Our approach is comprehensive, providing the required data, methodologies, and tools to comply with all regulatory requirements,” said David Silver, Head of Solutions at Clarity AI.
  • This integration offers SimCorp clients effortless access to top-quality data, further enhancing their investment decisions,” said Balslev Clausen.